Objective: To assess the role of serum copper in relation to ceruloplasmin and other peripheral markers of inflammation in Alzheimer disease (AD). Methods: The authors studied serum levels of copper, ceruloplasmin, and transferrin, as well as total peroxides, antioxidants, and other peripheral markers of inflammation in 47 patients with AD, 24 patients with vascular dementia (VaD), and 44 healthy controls. Biochemical variables were related to the patients' and controls' clinical status. Results: The authors found that copper (p Ͻ 0.001), peroxides (p ϭ 0.026), and ceruloplasmin (p ϭ 0.052) were increased and TRAP was decreased (p ϭ 0.006) in patients with AD, while no other markers of inflammation were altered. The calculation of the ratio between copper and ceruloplasmin suggested the presence in the serum of AD patients, but not of VaD or normal controls, of a large pool of non-ceruloplasmin-bound copper. Conclusions: Changes in the distribution of the serum copper components, consisting of an increase of a copper fraction not explained by ceruloplasmin, seem to be characteristic of Alzheimer disease and may be implicated in the pathogenesis of the disease.
Trace metals such as zinc, copper, and iron, and oxyradicals are reactive species involved in the neurodegeneration of Alzheimer disease (AD). 1, 2 Both iron and copper can catalyze Fenton's reactions, generating a flux of reactive oxygen species that can damage functional and structural macromolecules. 3 The toxicity of beta-amyloid (A␤) may also depend on copper-mediated free radical generation, and on copper-and zinc-induced deposition of amyloid plaques, as demonstrated by in vitro studies and in animal models of AD. [3] [4] [5] [6] We recently reported a perturbation of copper homeostasis specific to AD patients, consisting of elevation of serum copper levels and increased activity, in red blood cells, of the copper enzyme superoxide dismutase. [7] [8] [9] [10] Dysfunction of redox status and trace metals homeostasis could be related to an inflammatory response. Significant changes in copper absorption, transport, metabolism, or excretion do occur in inflammation, where plasma copper levels rise, along with levels of the acute phase copper-protein ceruloplasmin, the main carrier of fasting serum copper. 11 Ceruloplasmin is in fact increased due to an augmented rate of its hepatic synthesis and secretion. 11, 12 Much evidence supports the presence, in AD, of an inflammatory component leading to brain tissue damage, possibly through activated glia. 13 In addition there is yet somewhat controversial evidence of a concomitant inflammatory response in the general circulation of patients with AD. 14, 15 In order to assess the role of peripheral markers of redox trace metals in a putative inflammatory response in AD, we studied serum levels of copper, transferrin, total hydro-and lipoperoxides, and antioxidants, as well as a number of peripheral markers of inflammation, including ceruloplasmin. In addition, in order to identify changes most specific to patients with AD, we compared the results of the same assays in patients with vascular dementia (VaD). clinical evidence of neurologic or psychiatric disease. Twelve patients with AD and five patients with VaD had either poor quality MRIs or contraindications to the examination (e.g., metal prostheses); therefore, a CT scan was done to exclude other treatable causes of dementia. Six patients with AD and one patient with VaD did not complete the neuropsychological test battery. All controls underwent a neurologic examination and MMSE, yet only 16 agreed to undergo extensive neuropsychological testing and 12 consented to MRI.
Criteria for exclusion of both patients and controls were conditions known to affect copper metabolism and biologic variables of oxidative stress (e.g., diabetes mellitus, inflammatory diseases, Hodgkin's disease, recent history of heart or respiratory failure, chronic liver or renal failure, malignant tumors, alcohol abuse), on the basis of past medical history and screening laboratory tests. These tests included complete blood count, erythrocyte sedimentation rate (ESR), cholesterol, triglycerides, ferritin and fibrinogen levels, serum protein electrophoresis, renal function (creatinine, BUN), fasting glucose, electrolytes, vitamin B12, folic acid, and uric acid levels; thyroid function tests (thyroxin, triiodothyronine, and thyrotropin levels); liver enzymes (SGOT and SGPT), cardiac enzymes (CPK, LDH), bilirubin levels; serology for syphilis; and urine analysis. Patients and controls with abnormal values for thyroid, liver, kidney, or cardiac functions were also excluded from the study.
The study was approved by the local Institutional Review Board and all participants or legal guardians gave written, informed consent.
Biochemical and molecular investigations. Sera from fasting blood samples were collected in the morning and rapidly stored at Ϫ80°C. Serum copper concentration was measured following the method of Abe et al. (Randox Laboratories, Crumlin, UK), 20 and by an A Aanalyst 300 Perkin Elmer atomic absorption spectrophotometer equipped with a graphite furnace with platform HGA 800. 8 Measurements of biologic variables of oxidative stress are described in detail elsewhere. 21 Briefly, hydro-and lipoperoxide content was assessed by d-ROMs test (Diacron, Italy) and expressed in arbitrary units (U.CARR), 1 U.CARR corresponding to 0.08 mg/100 mL of hydrogen peroxide. 22 Normal range was between 230 and 310 U.CARR. 21, 22 Total Radical Trapping Antioxidant capacity or TRAP was assayed by the TAS kit (Randox Laboratories), based on published methods. 21, 23 The serum reference range is 1.30 to 1.77 mmol/L. 21, 23 Transferrin and ceruloplasmin were measured by immunoturbidimetric assays (Roche, Diagnostic, Germany) utilizing a goat anti-human transferrin antibody in TRIS/HCl buffer, 24 and a rabbit anti-human ceruloplasmin antibody in phosphate buffer. 25 All biochemical measures were automated on a Hitachi 912 analyser (Roche Diagnostics) and performed in duplicate. APOE genotyping was performed according to established methods. 26 Serum protein electrophoresis was carried out by means of the Beckman Paragon SPE agarose system with densitometric quantitation of the protein fraction (Analis, Namur, Belgium). Interleukin-1 ␤ (IL-1␤) and tumor necrosis factor ␣ (TNF␣) from serum were assessed with ELISA methods (DRG Instruments GmbH, Germany) based on appropriate and validated sets of monoclonal antibodies. 27, 28 Cognitive evaluation. Neuropsychological testing included the MMSE, 19 the Mental Deterioration Battery (MDB), 29 the Digit Span, 30 and the test of Corsi as described elsewhere. 8, 30 MRI evaluation. Brain MRI was performed using a 1.5 Tesla superconductor magnet. The imaging protocol consisted of axial T2 W double spin echo (SE) sequences and T1 W SE images in axial, coronal, and sagittal planes, with 5 mm slice thickness and intersection gap ϭ 0.5 mm. MR images were evaluated by two experienced neuroradiologists blinded to the patients' diagnoses or laboratory results, approaching total agreement (95%). Atrophy and white matter changes lesions were graded following standardized visual rating scales on plain MRI. [31] [32] [33] The degree of medial temporal lobe atrophy was evaluated with a ranking procedure and validated by linear measurements of the medial temporal lobe including the hippocampal formation and surrounding spaces occupied by CSF, following standardized criteria (five-point rating scale of medial temporal lobe atrophy [MTA]). 31 Generalized brain atrophy (ventricular and sulcal atrophy) was rated as present (1) or absent (0; global atrophy). The visual rating scale of white matter changes included the anatomic distribution as well as the severity of the lesions. Based on anatomic distribution, a distinction was made between areas of periventricular hyperintensities (PVH) (caps and rims) and deeper hyperintensities (including frontal, parieto-occipital, and temporal white matter hyperintensities [DWMH]; basal ganglia hyperintensities [BGH]; and infratentorial hyperintensities [ITH]). Large vessel cortical infarcts in the anterior, posterior, and medial cerebral artery were also evaluated. Presence of mass lesions and lobar hemorrhages were exclusion criteria from the study. 32, 34 Ultrasonographic examination of the cerebral vessels. The carotid and vertebral arteries were studied by means of color coded duplex ultrasonography (7.5 MHz probe; Acuson, Aspen) according to standardized criteria. 35 Detailed description of the sonographic procedures has been previously reported. 8 Particular attention was paid to detect both presence and degree of stenosis of atherosclerotic plaques in the carotid and vertebral arteries. The intima and media thickness (IMT) from the distal portion of the CCA was investigated in detail in each patient according to previous studies. 36 Intracranial vessels were also examined by transcranial Doppler (TCD Multidop T TCD-DWL, Germany), according to previously described methods. 37 Statistical analyses. AD and VaD patients and controls were described in terms of main demographic, genetic, and cognitive characteristics and statistically compared with analysis of variance (ANOVA) F, 2 , or Mann-Whitney tests. Both age and sex were considered as covariates in all parametric statistical analyses.
In order to assess the role of the copper and the other biologic variables in separating patients with AD, VaD, and healthy subjects, discriminant analysis was performed. Of note is that copper values were entered after logarithmic transformation. The analysis involved a linear combination of the independent variables that discriminates between the a priori defined groups, minimizing the misclassification rates. The findings of the discriminant analysis were verified by means of percentages of correct classification (both in the whole sample and after eliminating one case at a time according to the leave-one-out procedure).
The relationship between copper and ceruloplasmin was studied by means of polynomial regression analysis. This technique allowed us to choose the appropriate model, and, subsequently, two copper measures were calculated: copper explained and copper not explained by ceruloplasmin.
Eta-squared (the proportion of the dependent variable variance accounted for by the differences among groups) was also used as association measure. Finally, correlation analyses between biologic variables and neuropsychological scores (Pearson's r), and MRI atrophy and vascular measurements (Spearman's rho) were performed.
A p value less than 0.05 was considered significant in all statistical analyses, except when a correction for multiple comparisons was appropriate. Tukey's test was used when the homogeneity of variances could be assumed. When the variances were statistically heterogeneous, the Games-Howell procedure was applied. In order to avoid redundancies, the p values of the ANOVA (differences between controls, AD, and VaD) are reported in table 2 while the p values of the pairwise comparisons (adjusted for multiple comparisons) are reported in the text.
We used the SPSS 11.5 for Windows statistical software package (SPSS Inc., Chicago, IL).
Results. Patients and controls differed for age, controls being younger than patients with VaD (Tukey's p ϭ 0.019) and patients with AD (age overlap provided a Tukey's p of 0.054) (see table 1 ). The groups were not balanced for sex, since the proportion of women in the AD group was higher (76% vs 46% both in VaD and controls). AD and VaD patients did not differ for disease duration. The three groups differed for MMSE, as revealed by all pairwise comparisons (Tukey's p Ͻ 0.001). No differences for fasting glucose, vitamin B12, folic acid and uric acid levels, ESR, bilirubin levels, cholesterol, triglycerides, complete blood count, and hypertension among groups were evident. APOE ⑀4 allele was more frequent in both AD and VaD patients. Table 2 summarizes the data of copper, ceruloplasmin, peroxides, TRAP, and transferrin in patients with AD, VaD, and controls. Although the results on copper shown here were obtained by the colorimetric method, 23 those obtained by atomic absorption spectrophotometry assays were superimposable (intraclass correlation coefficient for consistency ϭ 0.89, p Ͻ 0.001). Copper (p Ͻ 0.001) and peroxides (p ϭ 0.008) were increased in patients with AD compared to controls (see table 2 ). Peroxides were higher in patients with VaD vs controls, though the difference did not reach significance (p ϭ 0.058).
TRAP was always lower in both groups of patients in comparison to controls (p ϭ 0.004 for AD and p ϭ 0.036 for VaD). The difference in ceruloplasmin content between AD and controls was 2.730 (95% CI: lower bound ϭ Ϫ0.130, upper bound ϭ 5.591), and that between VaD and controls was 0.003 (95% CI: lower bound ϭ Ϫ3.011, upper bound ϭ 3.061; p ϭ 0.987). However, after correcting for age and sex, the increase of ceruloplasmin observed in patients with AD only approximated significance (p ϭ 0.052). None of the oxidative and trace metal species measured correlated with age, except for transferrin, which was inversely correlated (r ϭ Ϫ0.20, p ϭ 0.037).
Discriminant analysis was applied to assess the potential implication of indices of copper metabolism in AD. In particular, we developed a model to identify which biologic (copper, ceruloplasmin, peroxides, and TRAP) and demographic variables (age and sex) could discriminate among patients with AD, patients with VaD, and controls. This procedure automatically identified two functions as linear combinations of the biologic variables. Function 1 was obtained combining three biologic variables high in the AD group-that is, copper, peroxides, and ceruloplasmin-that clearly separated AD patients from healthy controls (see figure E-1, Function 1 on the Neurology Web site at www. neurology.org). The second linear combination (Function 2) provided by the discriminant procedure was due almost exclusively to the TRAP contribution to the statistical model. This function distinguished patients with VaD from controls, TRAP being lower in the VaD group.
As a whole, this discriminant analysis was adequate in differentiating patients with AD from controls (correct classification of 80%, cross-validated, 73%), but not in separating patients with VaD from controls (correct classification rate of 69%, cross-validated, 59%). The discriminant power between AD and VaD could be improved, however, by adding MRI indices of white matter changes and atrophic burden (correct classification rate of 90%, crossvalidated, 79%). This analysis could not be applied to controls because of insufficient neuroimaging data. The most valuable variables in group discrimination were DWMH and copper. DWMH alone could discriminate AD from VaD with a classification rate of 77%, reaching 84% when copper levels were included in the analyses. The contribution of other variables was small (approximately 6%) and the total correct classification rate approached 90%.
In order to address the disequilibrium between the measured biologic markers, two ratios were calculated: copper:transferrin and copper:ceruloplasmin. ANOVA [F(2,106) ϭ 19.53; p Ͻ 0.001] and post hoc Games-Howell comparisons indicated that the copper:transferrin ratio was higher in AD vs controls and VaD (p Ͻ 0.001; figure  1 ). Comparisons of copper:ceruloplasmin ratios with ANOVA [F(2,94) ϭ 5.91; p ϭ 0.004] and post hoc Games-Howell comparisons confirmed higher values in patients with AD (p ϭ 0.028 vs controls, p ϭ 0.015 vs patients with VaD). Comparisons between controls and patients with VaD showed similar values for both ratios (p ϭ 0.953 and p ϭ 0.999; see figure 1 ). In order to explain the physiologic relationship between ceruloplasmin and copper we applied both lowess nonparametric and polynomial regression models to data obtained from the control group. After eliminating control subjects with abnormal influence statistics, the simple linear regression provided high goodness-of-fit. Pearson's r resulted equal to 0.75, indicating that about 56% of copper variability could be explained by ceruloplasmin. We calculated that, in healthy subjects, for each 10 points of ceruloplasmin levels increase, copper is expected to increase by 3.28 points (95% CI ϭ 2.15 to 4.41). On the basis of this physiologic relationship, we computed two copper measures: the first, copper explained by ceruloplasmin, corresponds to the theoretically expected level of copper, given a ceruloplasmin level; the second, copper not explained by ceruloplasmin, corresponds to the residual copper with respect to the regression line determined in controls. When both measures of copper levels were entered in the discriminant analysis, copper not explained by ceruloplasmin was able to differentiate AD from both VaD and controls (0.610, highest correlation with canonical discriminant function 1). Copper explained by ceruloplasmin, instead, did not contribute to the discriminant model (correlation coefficients ϭ 0.05 with canonical discriminant function 1 and ϭ 0.08 with canonical discriminant function 2). The higher discriminant power of copper not explained by ceruloplasmin is illustrated in figure 2 , where data were normalized with respect to the controls' mean.
No inflammatory processes were determined to be specific to AD in our patient sample, as the markers of inflammation we analyzed did not differ among the three groups (see (table 3) , confirming what was previously reported. 8 No correlation was instead present between cognitive testing and physiologic indices of peripheral inflammation, namely albumin, ESR, IL-1␤, TNF␣, and serum ␣1, ␣2, and ␥ fractions (results not shown). Correlation analysis from the Doppler examination revealed that no patient with AD had abnormal flow velocity in the cerebral arteries examined by Duplex sonography and TCD (results not shown). Moreover, none of the biochemical variables assayed correlated with ultrasound indicators of cerebrovascular burden, namely pres- ence of carotid plaque or stenosis, except for the IMT values that correlated with APOE ⑀4 genotype (Spearman rho ϭ 0.358; p Ͻ 0.005). Analyses of MRI data showed that presence of supratentorial atrophy (enlarged sulci, widened lateral and third ventricles) and atrophy of the temporal lobes (reduction in hippocampal volume) was prominent in AD subjects, while white matter changes and other deep-seated hyperintensities were more prevalent in VaD (see table E-2). Control subjects' values were consistent with those found in normal aging. Among MRI measurements and serum oxidative-trace metals values, there was a negative correlation between isolated MTA and TRAP (Spearman rho ϭ Ϫ0.451, p ϭ 0.001). Deep-seated ischemic changes, namely BGH, correlated with APOE ⑀4 genotype (Spearman rho ϭ Ϫ0.251, p ϭ 0.049). Correlation analyses of ⑀4 allele status with the biologic variables of oxidative stress and trace metals for all participants showed that presence of the APOE ⑀4 allele correlated only with lower TRAP concentrations, [t(99) ϭ Ϫ2.91, p ϭ 0.004].
Discussion. The results of this study show that the portion of serum copper unexplained by ceruloplasmin, as calculated on the ratio between ceruloplasmin and copper levels in healthy controls, can discriminate subjects with AD from both normal conrols and subjects with VaD better than copper explained by ceruloplasmin. This finding demonstrates an alteration of the ratio between copper and ceruloplasmin in this disease. Ceruloplasmin, an ␣-2 globulin with ferroxidase and copper transport functions, is a marker of both plasma copper status and inflammation. 12, 38 We had previously reported a relative elevation of total serum copper in AD, 8 although levels were within the usual reference range for copper of 10 to 22 mol/L. 20 Also another study analyzing indices of copper metabolism in AD showed that the ceruloplasmin-copper relationship probably represents the key issue in interpreting in vivo copper studies on AD, 39, 40 rather than absolute serum copper levels, making less relevant the discrepancy among studies that did 8, 41 or did not find differences in serum copper levels in AD. 42, 43 Normally, over 90% of human serum copper is considered to be tightly bound to ceruloplasmin, 44 even though some authors 11 suggested a value closer to 60% for ceruloplasmin-bound copper, similar to our study. The rest of the copper would be distributed among transcuprein (12%), albumin (12%), aminoacids (e.g., histidine), and small molecular weight complexes (0.5 to 5%), named exchangeable component. Studies on transgenic mouse models show that copper can bind and interact with APP (or A␤), which has been proposed to function as a copper/zinc metalloprotein, part of a failing metal homeostatic mechanism in AD. 45, 46 In particular, copper-binding APP has been hypothesized to represent a means for removing excess copper from brain tissue. 45, 47, 48 The excess of serum copper we estimated in AD could be explained by an efflux from cortical cells, as also proposed by some authors, 47 which would also explain why the rise observed is mainly due to copper unbound to ceruloplasmin, rather than the bound fraction biosynthesized, in fact, in the liver. This hypothesis is coherent with the APP-/-knockout mouse model, where absence of APP, proposed to balance cell copper concentration, is causative of the 40% increase in brain copper observed. Alternatively our results could be described by a failure of copper incorporation into APP in the liver. 45 In the APP-/-mouse model copper increases by 80% in the liver and 40% in the brain, while apparently no serum variations are found. 45 This situation closely resembles Wilson's disease, a degenerative condition where copper metabolism abnormalities are key to the pathogenesis, even though serum copper levels are within the normal range. In this disease, in fact, the micronutrients-associated fraction-that is, the exchangeable serum copper component-is extremely elevated. 49 In Wilson's disease copper is bound to small molecules that can easily reach organ tissues and cross the blood-brain barrier, which normally functions as an effective mechanism to control redox metals brain tissue levels. 50, 51 In studies on the distribution of copper among serum components in patients with cancer, variations in the four serum fractions were found and some patients with very high level of low-molecular weight copper were described. 11 The increase in ceruloplasmin unexplained copper calculated in our patients with AD is far from the unbound copper estimated in Wilson's disease, yet it approaches the levels described in patients with cancer and it could be toxic, partaking in A␤mediated toxicity of AD, as it can easily cross the blood-brain barrier. 51 In addition, our findings are coherent with the proposed activity of APP in balancing copper concentrations. 45, 46 A recent report showed that ingestion of low concentrations of copper (2 m) added to drinking water markedly impairs biometals homeostasis and increases brain parenchymal A␤ in rabbits fed cholesterol-supplemented diets. 52 The specific increase in total serum copper in our patients with AD was in the micromolar range, yet some authors have suggested that even increases in the nanomolar range could have an impact on AD pathogenesis. 47 Although we could not look, in vivo, for direct evidence of a toxic effect or a change in brain A␤ burden, we developed a statistical approach to assess the potential implication of copper in the pathogenesis of AD. Our aim was to estimate the specificity of the biologic indices of copper metabolism and oxidative stress in discriminating patients with AD from healthy and demented controls, and correlating them to the most relevant clinical characteristics of the disease. According to the discriminant analysis model, when patients with AD are compared to controls the biologic variables of trace metals and oxidative stress can correctly classify 80% of subjects. When the model is applied to AD and VaD populations and the MRI indices are included in the canonic function, they can discriminate 90% of patients. Indeed, a correlation between A␤ burden in CSF and copper in the serum is also suggested by preliminary evidence from our laboratory (manuscript in preparation).
While copper discriminates patients with AD from both controls and patients with VaD, the increase in peroxides seems to be reflective of a pro-oxidant status caused by an increase in redox copper. The decrease of TRAP, which is aspecific and is seen in both patients with AD and patients with VaD, may either reflect a primary defective antioxidant mechanism, conferring susceptibility to all dementias, or, on the contrary, may be secondary to brain tissue degeneration.
The ⑀4 frequencies of our patients with AD (19.3%) and healthy elderly controls (5%), much lower than frequencies in Northern Europe and the United States, are similar to those reported by studies documenting a dramatic decrease of the ⑀4 frequency from Northern to Southern Europe, and even from Northern to Southern Italy. 53, 54 In addition, our patients with VaD show an ⑀4 frequency relatively comparable to the patients with AD, as previously reported in other Italian samples. 55, 56 The overlap in APOE alleles frequencies in Italian patients with VaD and patients with AD, in addition to a geographic variation in the influence of this genotype over AD susceptibility, may reflect the partial neuropathologic and pathogenetic overlap between the two nosologic categories in general, as also documented by the ongoing debate over the adequacy of the international criteria used to distinguish AD from VaD. 57, 58 Much evidence suggests a role of inflammatory processes in AD pathogenesis, as well as a concomitant peripheral inflammatory response. 59 The concomitant increase in our patients with AD of the copper fraction explained by ceruloplasmin, a marker of inflammation, suggests that at least in part our findings could relate to general inflammatory mechanisms, despite the lack of significant differences in other peripheral markers of inflammation.
Our main finding is the probable existence in AD of an excess of copper not bound to ceruloplasmin, a serum component that might play a role in A␤mediated toxicity to the brain. 51 This serum copper component should also be sought in other neurodegenerative disorders. A study evaluating the reliability of copper in discriminating AD from Parkinson disease is currently in progress, and will help determine whether copper-mediated pathogenetic mechanisms are specific to AD.
